A Completely Safe, Non-Drug,
Natural Approach
to Normalizing Eye Function and Vision
Flavay® has been sold world-wide for vascular health and
extensively tested in humans for more than 50 years. The vascular
protective activity of Flavay® has been established by
many significant studies, demonstrating several important ways
in which Flavay® may protect the vascular health of the
eyes. Flavay® can protect the eyes from free radical damage,
support overall circulatory function, reinforce collagen structures
of the retina, enhance the eye’s ability to visually adapt
to different light environments, and protect the health of the
eye and retina.
Protecting the Smallest Blood
Vessels in the Eyes
The health of the eyes depends to a great extent on the integrity
of the fine vessels that supply blood to the area. Research
shows that Flavay® has the capacity to improve visual
performance in various ways.
Flavay® actually strengthens collagen in vascular walls
and capillaries (the smallest vessels), making the vessels stronger
and more elastic. Flavay® alters the membrane receptor
conformation of vascular walls, reducing the damaging effects
of the destructive enzymes elastase, collagenase and hyaluronidase,
by preventing them from attaching to and degrading vascular
walls. Flavay® further prevents destruction of vascular
walls by preventing the attachment to membranes of histamine
and hyaluronidase, both of which can decrease the strength of
vessel walls. Thus, in addition to preventing the root causes
of vessel occlusion, Flavay® strengthens vessels, thereby
reducing the risk of a rupture or hemorrhage, and helping to
prevent and relieve vascular fragility.
In clinical trials of patients with various types of retinal
diseases, including macular degeneration, diabetic retinopathy,
retinitis pigmentosa, and hemorrhagic and hypertensive retinopathy,
all persons given Flavay® showed significant improvement
following therapy. Flavay® has been shown to reduce pressure
in ophthalmic membranes by preventing abnormal leakage of fluids
into the orbital cavity and tissues.
Diabetic Retinopathy
Retinopathy is especially a problem for diabetics, who suffer
from greatly increased capillary permeability in their eyes.
The vascular wall and eye lens of a diabetic are especially
aggravated due to the nature of the disease.
There are basically two types of diabetic retinopathy, the
background type and the proliferative type. The background type
is characterized by microaneurisms (small sacs which develop
as a result of excessive vascular dilation), intraretinal hemorrhages,
yellowish waxy exudates, and swelling of the macula. The proliferative
type is characterized by the development of new vessels in the
retina and disk, proliferation of fibrous tissue, vitreous hemorrhage
and detachment of the retina. In either case, diabetic retinopathy
is one of the leading causes of blindness, and any agent that
can help to stem the effects of retinopathy is of value.
Many clinical studies conducted in Europe show that Flavay
greatly improved symptoms in patients with diabetic retinopathies
and maculopathies. In one study of 26 diabetic ophthalmic patients,
100 to 200 mg per day of Flavay® proved of therapeutic
value in controlling vascular incidents, which are characteristic
of diabetic retinopathy. Several weeks of treatment resulted
in noteworthy improvement in vascular incidents, with reduced
microaneurisms and diminished exudations, and overall improvement
in capillary fragility. The vision of those taking Flavay®
not only stopped decreasing, but even improved. Flavay®
protected cells against free radical damage, and it sealed the
microbleedings in the retina that obscure vision.
Clinical studies have conclusively demonstrated Flavay’s®
ability to stabilize microcapillaries in the retinal membranes
and it has therefore been licensed in France for treating diabetic
retinopathy. This shows that Flavay® should be part of
the daily nutritional regimen of every diabetic person.
Improving Visual Performance
in the Dark After Glare
Double-blind studies have demonstrated that Flavay® may
significantly improve visual performance in the dark after glare.
In one study of 100 workers who sit in front of computer monitors
or drive for a living, the administration of 200mg per day of
Flavay® enhanced visual adaptation from bright light.
This is the ability of the eyes to see well in a low-light situation
after being adjusted to bright light. In the eyes, a substance
known as rhodopsin, or visual purple, affects visual acuity
in low light. Rhodopsin is made by vitamin A and Flavay appears
to enhance the speed of rhodopsin activity, making it easier
to go from high to low light. Thus, just as Flavay® enhances
the activity of vitamin C in the body, it enhances an important
function of vitamin A.
"Radical Scavenger Effect"
of Flavay®
Protected by U.S. Patent No. 4,698,360
Flavay® is the product—used in the actual experiments—by
which Dr. Jack Masquelier established and patented the "radical
scavenger effect."
"[A] method for preventing and fighting
the harmful biological effects of free radicals
in the organism of warm blooded animals and more especially
human beings, namely cerebral involution, hypoxia following
atherosclerosis, cardiac or cerebral infarction, tumour
promotion, inflammation, ischaemia, alterations of the
synovial liquid, collagen degradation, among others.
The method consists in administering to said animals
and especially to human beings an amount, efficient
against said effects, of a plant extract with a proanthocyanidins
content which has a radical scavenger effect"—Dr.
Jack Masquelier, U.S. Patent No. 4,698,360.
The powerful free radical scavenging protection of Flavay®
is especially beneficial to the eyes, with its delicate microcapillaries.
Free Radicals, Cataracts and
Macular Degeneration
In the presence of oxygen, ultraviolet light generates free
radicals or precursors, and oxidative damage to lens proteins
leads to increasing opacity. In the young, repair mechanisms
exist, but as we age they become progressively less effective.
It has been hypothesized, through both animal and human studies,
that oxidation is involved in all types of cataracts and of
age-related macular degeneration. A number of epidemiologic
studies have found that age-related eye diseases consumed significantly
less antioxidants, particularly vitamin C, than did persons
who did not develop those eye conditions. Research shows that
Flavay® dramatically extends the lifetime of vitamin C
in the body, Flavay® provides its own powerful antioxidant
protection to the eyes and its tiny blood vessels, and Flavay®
enhances the protective effect of alpha-tocopherol (vitamin
E) in the eye and retina.
Proven Safety of Flavay®
After more than 50 years of human use, no adverse effects have been observed.
Furthermore, intensive biological, toxicological, pharmacological and analytical
research was conducted for the purpose of registering it as a medicine in France
and other countries in Europe. In one study, daily doses of up to 35,000 mg
for six months were determined to cause no adverse effects. Flavay® was
also clinically tested, in particular for all sorts of symptoms related to venolymphatic
insufficiencies (strenghthening veins, improving circulation and reducing edema
and inflammations). The spin-off is a goldmine of data: The rigorous testing
to meet the standards required by the health ministries of France, Germany and
other European countries demonstrate that Flavay® is highly bioavailable,
nontoxic, nonallergenic, noncarcinogenic, nonmutagenic, will not cause birth
defects, and is completely safe.
Dr. Masquelier’s unequaled manufacturing process has been conducted
for half a century at the very same facilities in France, and under the
control of French Pharmaceutical inspection. These time-proven standards
serve as a reliable assurance of the quality, consistency, bioavailability
and safety of Flavay®.
Who can take Flavay®?
Everyone, from the very young to elderly. Flavay® has no known contraindications
(conditions under which it should not be used). Flavay® is completely safe
and nontoxic. In fact, clinical trials have been conducted in which pregnant
women (troubled by varicose veins and other circulatory problems in the
legs) safely used Flavay®.
Why Trust Flavay®
Consumers need to know that the marketplace is full of imitations, various
“extracts” and derivative forms of Dr. Masquelier’s scientifically
proven and patented complex. Unfortunately, many have even used Dr. Masquelier’s
name and research in unauthorized ways to promote illegitimate products.
Flavay® is the name you can trust for the precisely
defined active polyphenol complex patented and perfected by the inventor, Dr.
Jack Masquelier, validated by the French Ministry of Health and documented by
a library of research consisting of many patents and hundreds of scientific
papers, articles, doctorate theses, lectures and presentations. For quality,
consistency, bioavailablity and safety, consumers may rely upon Flavay®.
Best Protection for the Health
of Your Eyes and Retinas
Now available in the United States, Flavay®
is the actual product that has been licensed and sold in France
for protection against diabetic retinopathy. As discussed above,
Flavay® can protect the eyes from free radical damage,
support overall circulatory function, reinforce collagen structures
of the retina, enhance the eye’s ability to visually adapt
to different light environments, and protect the health of the
eye and retina.
Statements made herein have not been
evaluated by the Food and Drug Administration. These products are not intended
to diagnose, treat, cure or prevent any disease.
Masquelier, J. Plant extract
with a proanthocyanidins content as a therapeutic agent having
radical scavenging effect and use thereof. U.S. Patent No. 4,698,360,
1987.
Masquelier, J. A lifetime devoted to OPC and Pycnogenols. Alfa
Omega Editrice, Pub., 1996.
Schwitters, B., Masquelier, J. OPC in practice. Alfa Omega Editrice,
Publishers, 1995.
Kilham, C., Masquelier, J. OPC: The miracle antioxidant. Keats
Publishing, Inc., 1997.
Packer, L.,, et al. Antioxidant food supplements in human health.
Academic Press, 1999.
Mindell, E., et al. Earl Mindell’s vitamin bible for the
21st century. Warner Books, Inc., 1999.
Passwater, R.A. The antioxidants: the nutrients that guard your
body. Keats Publishing, Inc., 1985.
Barilla, J. et al. The nutrition superbook: volume 1: the antioxidants.
Keats Publishing, Inc., 1995.
Facino RM, et al. Free radical scavenging action and anti-enzyme
activities of procyanidines from Vitis vinifera. A mechanism for
their capillary protective action. Arzneimittelforschung, 44:
592-601, 1994.
Kuttan R, et al. Collagen treated with catechin becomes resistant
to the action of mammalian collagenase. Experientia, 37: 221-223,
1981.
Masquelier, J., et al. Stabilization du collagene par les oligomeres
procyanidoliques. Acta Therapeutica, 7:101-105, 1981.
Masquelier, J. Aspects pharmacologiques nouveaux de certains flavonoides.
A Vie Medical 12:1969.
Laparra, J., et al. Etude pharmaco-cinetique des oligomers procyandoliques
totaux du raisin. Acta Therapeutica, 4, 1978.
Laparra, J., et al. Etude pharmacocinetique des oligomeres flavonoliques.
Plantes med et phyto, Tome XI, pp. 133-142, 1977.
Robert A.M.; Groult, N.; Six, C.; Robert, L. Etude de l’action
des oligomeres procyanidoliques sur des cellules mesenchymateuses
en culture. Ii l’attachment des fibres elastiques aux cellules.
(Study of the effect of procyanidolic oligomers on mesenchymal
cells in culture. Ii attachment of elastic fibers to the cells.)
Pat Biol, (30)6:601-7, 1990.
Porter, Lawrence J., Wong Rosalind Y. Chan, Bock G. The molecular
and crystal structure of (+)-2,3-trans-3,4-trans-leucocyanidin
[(2r,3s,+r)-(+)-3,3’, 4.4’, 5.7’-Hexahydroxyflavan]
dihydrate, and comparison of its heterocyclic ring conformation
in solution and the solid state. Journal of the Chemical Society;
Perkin Transactions I 1985. pp. 1413-17.
Masquelier, J. Proanthocyanidins et radicaux libres. 1985.
Uchida, S., et al. Condensed tannins scavenge active oxygen free
radicals. Med Sci Res, (15) 1987. pp. 831-832.
Ariga, T. Radical scavenging action and its mode in procyanidins
b-1 and b-3 from azuki beans to peroxyl radicals. Agric Biol Chem,
54(10) 1990. pp. 2499-2504.
Da Silva, R., et. al. Radical scavenger capacity of different
procyanidins from grape seeds. Presented at a symposium, “Free
radicals in biotechnology and medicine.” Royal Society Of
Chemistry, London January 1990, pp. 79-80.
Bauman, J., Wurm, G., Bruchhausen, F. “Hemmung der prostagladinsynthetase
durch flavonoide und phenolderivate im vergleich nit deren 02
radikalfangereigenschaften” Arch Pharm, (Weinheim) 313 (1980)
pp. 330-337.
Flesch M., et al., Effects of red and white wine on endothelium-dependent
vasorelaxation of rat aorta and human coronary arteries. Am J
Physiol 1998;275:1183-94.
Fitzpatrick, D.F., Fleming R.C., Bing B, Maggi DA, O'Malley RM.
Isolation and characterization of endothelium-dependent vasorelaxing
compounds from grape seeds. J Agr & Food Chem In press.
Fitzpatrick, D.F., Maggi D, Bing B, Coffey RG. Vasorelaxation,
endothelium, and wine. BioFactors 1997;6:455-459.
Fitzpatrick, D.F., Hirschfield SL, Ricci T, Jantzen P, Coffey
RG. Endothelium-dependent vasorelaxation caused by various plant
extracts. J Cardiovasc Pharmacol 1995;26:90-95.
Fitzpatrick, D.F., Hirschfield SL, Coffey RG. Endothelium-dependent
vasorelaxing activity of wine and other grape products. Amer J
Physiol 1993;265:H774-H778.
Facino, R.M., et al. Free radical scavenging action and anti-enzyme
activities of procyanidines from vitis vinifera. A mechanism for
their capillary protective action. Arzneimittelforschung, 44:
592-601, 1994.
Kuttan, R., Donnelly, P.V., Di Ferrante, N. Collagen treated with
catechin becomes resistant to the action of mammalian collagenase.
Experientia, 37: 221-223, 1981.
Masquelier, J. Procyanidolic oligomers. J Parums Cosm Arom, 95:
89-97, 1990.
Tixier, J.M., et al. Evidence by in vivo and in vitro studies
that binding of pycnogenols to elastin affects its rate of degradation
by elastases. Biochem Pharmacol, 33: 3933-3939, 1984.
Kakegawa, H., et al. Chem. Pharm. Bull. 33:5079, 1985.
Harmand, M.F., Blanquet, P. The fate of total flavanolic oligomers
extracted from ‘vitus vinifera l.’ in the rat. European
Journal of Drug Metabolism and Pharmaccokinetics. 1978, No. 1
pp. 15-30.
Delrieu, P., Ding J., Escande, B., Samain, D. Free-radical scavenging
activity of proanthocyanidolic oligomers encapsulated in glycospheres:
an in vivo and in vitro study. Cosmetology Department & S
Biovectors, Ramonville St. Agne France. pp. 1-9.
Meunier, M.T., Villie, F., et al. Inhibition of angiotensin i
converting enzyme by flavanolic compounds: in vitro and in vivo
studies. Planta Medica, May 26, 1986. pp. 12-15.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-oedenme de la patte. Sanofi Res Toul Cedex
Fr, pp31-40.
Barbier, A., et al. Activite angioprotectrice des oligomeres procyanidolques
chez l’animal-activite aniagoniste vis-a-vis des mediateurs
de l’inflamation. Sanofi Res Toul Cedex Fr, pp. 31-40.
Dubos, C., Durst, G., Hugonot, H. Evolution de la resistance capillaire,
spontanement ou artificiellement diminuee par l’action d’une
substance capillaro-toxique chez des personnes agees--action benefique
d’un agnet actif sur la micro-circulation: l’Endotelon.
Inform. Therapeut. 1980. pp. 302-305.
Dartenuc, J.Y., et al. Resistance capillaire en geriatrie etude
d’un microangioprotecteur-Endotelon. Bordeaux Med. 13:903-7,
1990.
Lagrue, G., Olivier-Martin, F., Grillot, A. “Etude des effets
des oligomeres du procyanidol sur las resistance capillaire dand
l’hypertension arterielle et certaines nephropathies.”
Sen. Hosp. Paris 18-25 Septembre, 1981.
Beylot, C., Bioulac, P. Essai therapeutique d’un angioprotecteur
peripherique, l’Endotelon. Actualite Therapeutique Gaz. Med.
de France (87)22:2919-24, 1980.
Lesbre, F.X., Tigaud, J.D. Effect de l’Endotelon sur l’indice
de fragilite capillaire dan une population specifique: les sujets
cirrhotiques. Gaz. Med. de France, (90)24 1983.
Sarrat, L. Abord therapeutique des troubles fonctionnels des membres
inferieurs par un microangioprotecteur l’Endotelon. Bordeaux
Med, 11:685-8, 1981.
Delacroix, P. Etude en double aveugle de l’Endotelon dans
l’insuffisance veineuse chronique. Therapeutique, la Revue
de Medicine, (27-28) Sept. 1981. pp. 1793-1802.
Thebaut, J.F, Thebaut, P., Vin, F. Etude de l’Endotelon dand
les manifestations fonctionnelles de l’insuffisance veineuse
peripherique-resultats d’une etude en double aveugle portant
sur 92 patients.” Gazette Medicale, (92)1, 1985. pp. 96-100.
Chang, W.C., Hsu, F.L. Inhibition of platelet aggregation and
arachidonate metabolism in platelets by procyanidins. Prostagland
Leukotri Essent Fatty Acids, 38:181-8, 1989.
Masquelier, J. Pycnogenols: recent advances in the therapeutical
activity of procyanidins. Supplement of Planta Medica, Journal
of Medicinal Plant Research and Journal of Natural Products, July
1980 pp. 243-256.
Henning, B., et al. Lipid peroxidation and endothelial cell injury:
implications in atherosclerosis. Free Rad Path & Med, (4)1988
pp. 99-106.
Masquelier, J. “Les procyanidols du vin leur role dans l’alcoolisme.”
pp. 88-93.
Gazave, J.M. “Notions recentes sur les capillaires”
unpub. bulletin from the Laboratoire De Physiologie Patholigie
pp. 26-29.
Ruf, J.C. Wine and polyphenols related to platelet aggregation
and atherothrombosis. Office International Vigne et du Vin, Nutrition
and Health Unit, Paris France; Drugs under Experimental and Clinical
Research (Switz.) 25/2-3 (125-131), 1999.
Blaszo, G. Gabor, M. Oedema-inhibiting effect of procyanidin.
Acta Physiologica Academiae Scientiarum Hungaricae, Tomus 56(2):235-240,
1980.
Tayau, M.F, LeFevre, G. Action du leucocyanidol sur l’hyalaluronidase.
Bull Soc Pharm Bordeaux, 95:132-136, 1956.
Lamy, M. Utilization des oligomeres procyanidoliques en gynecologie.
Essai Therapeutique Tomel (14) Sept. 2, 1981. pp. 1021-22.
Henriet, J.P “Une Etude Exemplaire Pour Un Phlebotrope: l’etude
EIVE.’ Unpub., pp. 77-83.
Pfister, A., Simon, M.T., Gazave, J.M. Sites de fixation des oligomeres
procyanidoliques dans la paroi des capillaires sanguins du poumon
decobaye. Acta Therapeutica (8) 1982. pp. 223-237.
Kuttan, R., Donnelly, P., Di Ferrante, N. “Collagen treated
with (+) -catechin becomes resistant to the action of mammalian
collagenase.” Laboratory of Connective Tissue Research, Dept.
of Biochem. Baylor Col. of Med., Houston TX. 28, May, 1980.
Gendre, P., Laparra, J., Barraud, E. “Effect protecteur des
oligomeres procyanidoliques sur le lathyrisme experimental chez
le rat.” Ann. Pharm. Francaises, (43)1, 1985 pp. 61-73.
Corbe, C., Boissin, J.P., Siou, A. Light vision and chorioretinal
circulation. Study of the effect of procyanidolic oligomer (Endotelon).
Jn. Fr. Opthalmol, (11)5:453-460, 1988.
Boissin, J.P., Corbe C., Siou, A. Chorioretinal circulation and
dazzling: use of procyanidol oligomers (Endotelon). Bull Soc Ophtalmol
Fr, 88(2):173-4, 177-9, 1988.
Proto, F. et al. Electrophysical study of vitis vinifera procyanoside
oligomers effects on retinal function in myopic subjects. Ann
Ott Clin Ocul, 114:85-93, 1988.
Saracco, J.B., Estachy, G.M. Etude d l’Endotelon en opthalmologie.
Gaz Med de France, 88:2035-2038, 1981.
Scharrer, A., Ober, M. Anthocyanosides in the treatment of retinopathies.
Klin Monatsbl Augenheilkd, 178:386-389, 1981.
Corbe, C., et al. Microangiopathy of the retina. J. Fr. Opthalmol,
11:453, 1988.
Verin, M.M., Vildy, A., Maurin, J.F., Retinopathies et O.P.C.
Bordeaux Medicale, (16)11. pp. 1467-74, 1978.
Soyeux, A. et al. Endotelon. Diabetic retinopathy and hemorheology.
Bull Soc Ophtalmol Fr. 87(12):1441-4, 1987.
Fromantin, M. “Les oligomeres procyanidoliques dans le traitement
de la fragilite capillaire et de la retinopathie chez les diabetiques.
A propos de 26 cas.” Med Int, 16(11):432-434, Nov. 1981.
Arne, J.L. Contribution a l’etude des oligomeres procyanidoliques:
Endotelon, dans la retinopathie diabetique (a propos de 30 observations).
Gaz. Med. de France, Vol. 89, No. 30, Oct. 8, 1982.
Baruch, J. Effect of Endotelon in postoperative edema. Results
of a double-blind study versus placebo in 32 female patients.
Ann Chir Plast Esthet 29(4):393-5, 1984.
Rao, C.N. et al. Influence of bioflavonoids on the collagen metabolism
in rats with adjuvantinduced arthritis. Ital J Biochem. 30:54-62,
1981.
Gabor, M. Pharmacologic effects of flavonoids on blood vessels.
Angiologica, 9:355-374, 1972.
Havsteen, B. Flavonoids, a class of natural products of high pharmacological
potency. Biochem Pharmacol, 32:1141-48, 1983.
Reimann, H.J., Lorenz, W., Fischer, M., Frölich, R., Meyer,
H.J. Berkhauser Verlag, Vol. 7/1, Univ. of Marburg/Lahn, Ger.,
1977.
Masquelier, J. Action protectrice du vin sur l’ulcere gastrique.
Resultats, p. 61.
Amella, M., et al. Inhibition of mast cell histamine release by
flavonoids and bioflavonoids. Planta Medica, 5116-20, 1985.
Packer, L., et al. The antioxidant miracle: your complete plan.
John Wiley & Sons, Inc., 1999.
Shaw, R. How [Australian] PycnoGenol [MASQUELIER’s®]
Helps Sports People.
Masquelier, J. Procyanidolic oligomers (leucocyanidins). Parfums
Cosmet Arom 95:89-97, 1990.
Pecking, A., Desprez-Curely, J.P., Megret, G. Oligomers procyanidoliques
(Endotelon) dans le traitement des lymphoedemes post-therepeutiques
de members superieurs. Symposium Satellite, Congres International
d’Angiologie, Toulouse, France, 4-7 Oct. 1989.
Laparra, J., Michaud, J. Masquelier, J. Action des oligomeres
procyanidoliques sur le cobaye carence en vitamin c. Tavaux Originaux,
University of Bordeaux, 1976.
Masquelier, J. Action comparee de divers facteurs vitaminiques
p sur l’oxydation de l’acide ascorbique par les ions
cuivriques. Bull. de la Societe de Chimie Biologique XXXIII (3-4)
1951. pp. 302-304.
Masquelier, J. Action comparee de divers facteurs vitaminiques
p sur l’acide ascorbique-oxydase. Bull. de la Societe de
Chimie Biologique XXXIII (3,4) 1951. pp.304-306
Kakegawa, H., Matsumoto, H., Endo, K., Satoh, T., Nonaka, G.,
Mishioka, I. “Inhibitory effects of tannins on hyaluronidase
activation and on the degranulation from rat mesentery mast cells.”
Chem. Pharm. Bull. 33(11)1985. 5079-5082.
Reiman, H.J., Lorenz, M., Fischer, R., Frolich, H., Meyer, J.
“Histamine and acute haemorrhagic lesions in rat gastric
mucosa: prevention of stress ulcer formulation by (+)-catechin,
an inhibitor of specific histidine decarboxylase in vitro.”
Dirkhauser Verlag,Vol. 7/1, 1977.
Pariente, J.J. Parientl-Amsellem, J. “Les oedemes post-traumatoqies
chez le sportif: essai controle de l’Endothelon.” Actualite
Therapeutique 90(3) 2/11 1983 pp. 231-235.
Masquelier, J., et al. “Flavonoids et Pycnogenols” Int
J Vit Nut Res, (49)3:307-311, 1979.
Yu, C. L. et al. Mutagenicity of proanthocyanidins. Food Chem.
Toxicol. 25(2):135-9, 1987.
Pantaleoni, G.C., Quaglino, D. Univerisity of Aquila Pharmacol-Toxicologica
Report, 1971.
Laparra, J., et al., Acta Therapeutica, 4:233, 1978.
Volkner, Wolfgang Muller, Ewald, Micronucleus assay in bone marrow
cells of the mouse with Pycnogenol. Cytotest Cell Research GmbH
& Co., projects 143010 & 143021; Feb. 1989.
Acute and chronic toxicity tests. International Bio-Research,
Inc., Hanover, Germany, 1967-1971.
Dumon, M., Michaud, J., Masquelier, J. Proanthocyanidin content
in vegetable extracts to be used in the preparation of medicines.
Bull. Soc. Pharm. Bordeaux, 129:51-65, 1990.
